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Abstract
We have developed a genetic system, called degrakine, that specifically and stably inactivates 
chemokine receptors (CKR) by redirecting the ability of the HIV-1 protein, Vpu, to degrade CD4 
in the endoplasmic reticulum (ER) via the host proteasome machinery. To harness Vpu’s 
proteolytic targeting capability to degrade new receptors, we fused a chemokine with the C 
terminal region of Vpu. The fusion protein, or degrakine, accumulates in the ER, trapping and 
functionally inactivating its target CKR. We have demonstrated that degrakines based on SDF-1 
(CXCL12), MDC (CCL22) and RANTES (CCL5) specifically inactivate their respective receptor 
functions. Using a retroviral vector expressing the SDF-1 degrakine, we have established that 
CXCR4 is required for the homing of hematopoietic stem/progenitor cells (HSPC) to the bone 
marrow immediately after transplantation. Thus the degrakine provides an effective genetic tool to 
dissect receptor functions in a number of biological systems in vitro and in vivo.
CKRs are G protein–coupled receptors (GPCRs) that have critical roles in controlling the 
migration of HSPCs and mature leukocytes and that participate in important 
pathophysiological processes including inflammation, allograft rejection, autoimmunity, 
viral infection and lymphoid development1–5. Approximately 20 CKRs and over 40 
chemokines are encoded in the mouse or human genome1,2. Chemokines are subdivided into 
CXC (alpha), CC (beta), C (gamma) and CX3C (delta) classes, depending on the position of 
conserved cystine residues in the polypeptide. Each CKR is specific to one or multiple 
chemokines, and each chemokine can bind to one or multiple CKRs. Despite recent interest 
in chemokines and CKRs, their involvement in HSPC and leukocyte migration remains 
poorly defined because of the large number of family members, cross-reactivity and a lack 
of efficient genetic tools to dissect their functions.
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Gene targeting in mice has been done for a limited number of CKRs, but it is time-
consuming and expensive to generate knockout mice. In addition, it is difficult to breed mice 
with mutations in multiple CKRs because the genes encoding them are closely linked at two 
chromosomal loci2. A common approach to studying CKR function is through the use of 
blocking antibodies, an approach that has limitations including toxicity and the lack of target 
specificity and in vivo efficacy6. Another method, the intrakine system, inhibits the level of 
CKR surface expression by sequestration of the target CKR in the ER7. However, the 
intrakine seems to have a paracrine activity, probably as a result of secretion of the intrakine 
protein out of the cell8, and this method may also lead to toxic accumulation of intrakine-
CKR protein complexes in the ER. More recently, RNA interference technology has been 
used to knock down gene function in vitro and in vivo9–13.
Many viruses have intricate, naturally evolved mechanisms to interact with receptors on 
infected cells and thereby elude the host’s immune system and facilitate replication14,15. 
HIV-1 uses its envelope and Vpu proteins to specifically target CD4 for degradation in the 
ER14–16. The C terminal region of Vpu mediates this interaction by binding with the β-
TrCP–Skp1 protein complex, which leads to CD4 ubiquitination and degradation16,17. 
Phosphorylation of the serine residues Ser52 and Ser56 in Vpu is critical for β-TrCP binding 
and CD4 degradation, although Vpu itself is resistant to ubiquitination and degradation16,18. 
To harness Vpu’s proteolytic targeting capability to degrade new receptors, we fused a 
chemokine with the C terminal region of Vpu. The chemokine–VpuC fusion protein 
(degrakine) is designed to specifically downregulate the surface expression and inhibit the 
function of its target CKR. Combining the degrakine with retroviral gene transfer, we have 
developed a genetic system to rapidly and specifically inactivate CKRs in either human or 
mouse cells in vitro and in vivo.
The prototype degrakine is designed with the chemokine SDF-1α (CXCL12), which 
specifically binds CXCR4 (refs. 19–22). SDF-1 is expressed from a single gene, but has two 
isoforms, SDF-1α and SDF-1β, that are generated by alternate splicing23. Although 
originally identified as a pre-B-cell growth factor expressed in mouse bone marrow21,23–25, 
SDF-1α elicits a potent migratory response from monocytes, T cells and HSPCs21,25,26. 
Mutations in either SDF-1 or CXCR4 in mice lead to embryonic lethality with neurological 
and hematological abnormalities27,28. Additionally, CXCR4 is required for stable 
engraftment of human HSPC cells into the bone marrow of NOD-SCID mice and of mouse 
fetal liver cells into lethally irradiated recipient mice28,29. However, it remains unclear 
whether CXCR4 mediates HSPC homing to the bone marrow, retention and proliferation 
within the bone marrow, or long-term maintenance of progenitor cells. Using the SDF-1 
degrakine, we show that CXCR4 plays a role in HSPC homing to the bone marrow 
immediately after HSPC transplantation.
RESULTS
Degrakine design
The degrakine protein comprises two domains. The C-terminal domain is aa28–81 (VpuC) 
of Vpu, which recruits the proteasome16. The N-terminal domain consists of a chemokine 
(or a chemokine receptor binding domain, CRBD) (Fig. 1a). The prototype degrakine is 
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constructed with SDF-1 and a hemagglutinin tag as the CRBD. The murine stem cell virus 
long terminal repeat (MSCV LTR) drives expression of the SDF-1 degrakine fusion protein, 
and a cytomegalovirus (CMV)-driven enhanced green fluorescent protein (EGFP) marker is 
included in the retroviral vector (Fig. 1a). In the proposed SDF-1 degrakine pathway, the 
degrakine localizes to the ER, traps the target CKR (CXCR4) in the ER and recruits the 
proteasome to degrade the target CKR (Fig. 1b).
Degrakine ER localization, stable expression and noncytotoxicity
The SDF-1 degrakine protein was expressed and localized to the ER. Protein expression was 
confirmed by western blotting with anti-Vpu and anti-hemagglutinin (data not shown). ER 
localization was determined by coexpression of the ER-accumulated YFP-KDEL protein. 
Staining of human osteosarcoma U2OS cells with anti-hemagglutinin showed that the 
SDF-1 degrakine colocalized with YFP-KDEL in the ER (Fig. 2a).
SDF-1 contains a signal peptide sequence that directs its transport to the ER and into the 
secretory pathway21. Thus the SDF-1 degrakine could be secreted from the cell. To monitor 
this possibility, we analyzed human embryonic kidney 293T cells and SupT1 T-lymphocyte 
cells expressing the indicated vectors for SDF-1 secretion by enzyme-linked immunosorbent 
assay (ELISA). A control vector expressing SDF-1 was used to determine maximum 
secretion without ER retention. Additionally, a construct expressing the SDF-1 intrakine, 
SDF-1KDEL7, was used to demonstrate KDEL-mediated retention of SDF-1 within the ER. 
293T cells transiently expressing SDF-1 and SDF-1KDEL both secreted SDF-1 efficiently 
into the medium (~2.5 nM, Fig. 2b). In contrast, SDF-1VpuC and SDF-1VpuC2/6 secreted 
66% less SDF-1 (Fig. 2b). In stably transduced SupT1 cells, the presence of SDF-1VpuC 
construct resulted in an 89% and 67% decrease in secreted SDF-1 as compared with SDF-1 
and SDF-1KDEL, respectively (Fig. 2c). The SDF-1VpuC2/6 protein with mutations 
inhibiting Vpu’s interaction with βTrCP was secreted in amounts similar to those of 
SDF-1VpuC (Fig. 2b,c). Thus, the SDF-1 degrakine is retained within the cell and may 
contain an unidentified ER retention motif because no known ER retention signal has been 
identified in the VpuC domain.
Expression of the SDF-1 degrakine did not affect cell viability or proliferation in a number 
of human cell lines, primary mouse thymocytes and mouse HSPCs. Comparable rates of 
proliferation were observed over 9 d in culture in parental SupT1 cells and cells transduced 
with vector or SDF-1VpuC (Fig. 2d). Cells transduced with vector or with SDF-1VpuC were 
also monitored by fluorescence-activated cell sorting (FACS) for EGFP expression at 2 d 
and 3 weeks after transduction. Constant levels of EGFP expression were observed at both 
time points (Fig. 2e), showing that the degrakine protein is not cytotoxic. In addition, stable 
expression of the degrakine was also observed in primary mouse bone marrow cells cultured 
for 12 d in vitro (Fig. 2f). Therefore, the degrakine fusion protein does not affect cell 
viability or proliferation in various types of cells.
Stable and specific suppression of CXCR4 expression
The SDF-1 degrakine induced rapid and stable downregulation of CXCR4 surface 
expression in SupT1 cells and Jurkat lymphoblastic leukemia cells. Three days after 
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transduction, SupT1 cells showed a ~70% reduction in CXCR4 surface expression 
compared with the vector control, and after 1 week in culture, CXCR4 was downregulated 
by ~90% (Fig. 3a). At 3 and 6 weeks in culture, the SDF-1 degrakine maintained stable 
CXCR4 downregulation (Fig. 3b). Surface staining of CD4 and MHC-I confirmed that the 
VpuC-based degrakine did not alter the expression of CD4 or MHC-I as full-length Vpu14,17 
(Fig. 3c).
β-TrCP is involved in receptor downregulation
The degrakine system requires the interaction of VpuC with β-TrCP for efficient CKR 
downregulation. This was demonstrated using a VpuC mutant, VpuC2/6, which contains 
alanine substitutions at Ser52 and Ser56. These mutations block the interaction between Vpu 
and β-TrCP, which leads to the loss of Vpu-mediated CD4 degradation16,18. SDF-1VpuC2/6 
therefore binds and sequesters CXCR4 in the ER, but cannot recruit the proteasome. We 
also used the SDF-1 intrakine, SDF-1KDEL7, as a control for CXCR4 downregulation by 
ER sequestration without degradation. Cells expressing vector, SDF-1KDEL, SDF-1VpuC 
or SDF-1VpuC2/6 were analyzed for CXCR4 expression by FACS. SDF-1VpuC inhibited 
CXCR4 expression by ~90% (Figs. 3a and 4a). In contrast, SDF-1VpuC2/6 and 
SDF-1KDEL (constructs that only sequester CXCR4 in the ER) showed a ~60–70% 
decrease in CXCR4 surface expression (Fig. 4a). These results demonstrate that the 
interaction between Vpu and β-TrCP is important in efficient CXCR4 downregulation by the 
SDF-1 degrakine.
To demonstrate VpuC-mediated degradation of CXCR4, we measured total CXCR4 protein 
in transduced Jurkat cells by western blotting. NIH3T3 cells stably expressing human 
CXCR4 were used as a positive control. Total levels of CXCR4 were similar in cells 
expressing vector or SDF-1VpuC2/6, but lower in cells expressing SDF-1VpuC (Fig. 4b). 
The expression levels of SDF-1VpuC and SDF-1VpuC2/6 were similar, as determined by 
western blotting with anti-VpuC (data not shown). Therefore, the interaction between VpuC 
and β-TrCP leads to the degradation of CXCR4 by the SDF-1 degrakine.
Functional inactivation of target CKRs by degrakines
SDF-1 binding to CXCR4 resulted in the release of intracellular calcium into the cytosol 
(calcium influx)30. Intracellular calcium influx in response to SDF-1 in cells expressing the 
indicated proteins was measured by FACS. SDF-1VpuC inhibited the ability of SDF-1 to 
induce calcium influx even at 100 nM, indicating that the SDF-1 degrakine efficiently 
inactivated CXCR4 function (Fig. 5a).
CXCR4 mediated cell migration in response to SDF-1 (ref. 21,22). Mock or vector control 
cells migrated efficiently in response to 1 nM and 10 nM of SDF-1, with a typical 
oversaturation response at 100 nM. In contrast, cells expressing SDF-1VpuC showed no 
response to 1 nM and 10 nM of SDF-1 and only a low migration response to 100 nM of 
SDF-1 (Fig. 5b), a result consistent with low CXCR4 expression. The reduced migration of 
SDF-1VpuC cells in the absence of exogenous SDF-1 was probably a result of SDF-1-like 
activity in the culture medium. These experiments show that both CXCR4-mediated calcium 
influx and chemotaxis are inhibited by the SDF-1 degrakine.
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Two additional degrakine constructs were tested to demonstrate the specificity and general 
utility of the system. RantesVpuC and MDCVpuC were designed to inhibit CCR5 and 
CCR4, respectively. Human acute monocytic leukemia THP-1 cells expressing both CXCR4 
and CCR5 (ref. 31) were used to demonstrate the specific targeting of CXCR4 and CCR5 by 
SDF-1VpuC and RantesVpuC, respectively. The migration response to SDF-1 was inhibited 
by 81% only in THP-1 cells expressing SDF-1VpuC (Fig. 5c), whereas response to MIP-1β 
was reduced 65% in THP-1 cells expressing RantesVpuC (Fig. 5d). Similarly, MDCVpuC-
transduced mouse thymocytes, which express CCR4 (ref. 32), showed a 66% reduction in 
migration response to 100 nM MDC as compared with vector or SDF-1VpuC (Fig. 5e). 
Thus, the degrakines specifically inactivated their target CKR functions. Taken together, 
these results suggest that the degrakine system is applicable to inactivating chemokine 
receptors in general.
CXCR4 is required for the homing of HSPC to the bone marrow
SDF-1 is a potent migratory chemokine for HSPC cells in vitro26,33,34. We used the SDF-1 
degrakine to determine whether CXCR4 is required for the homing of HSPC to the bone 
marrow in vivo. Bone marrow cells from B6/Ly5.2 mice were enriched for cKit+ progenitor 
cells35 and transduced with the MSCV-based retroviral vectors. Stable EGFP expression in 
vector or SDF-1 degrakine–transduced progenitor cells was observed in vitro, and degrakine 
expression was confirmed by anti-Vpu western blotting 12 d after transduction (Fig. 2f). The 
SDF-1 degrakine is therefore not cytotoxic to mouse HSPCs. Progenitor cells expressing 
SDF-1 or RANTES degrakines were assayed for their migratory response to 10 nM and 50 
nM of SDF-1. Cells expressing SDF-1VpuC showed a 60–70% reduction in migration 
response to SDF-1 whereas cells expressing the RANTES degrakine showed normal 
responses to SDF-1 (Fig. 6a). To investigate CXCR4’s role in HSPC homing during 
transplantation, we injected intravenously B6/Ly5.2 bone marrow cKit+ cells expressing 
vector, SDF-1VpuC or MDCVpuC into lethally irradiated B6/Ly5.1 recipient mice. Three 
hours after transplantation, bone marrow cells were harvested and analyzed by FACS for 
Ly5.2 (donor) and EGFP (degrakine-positive) expression. SDF-1VpuC inhibited short-term 
homing of progenitor cells by ~40% (Fig. 6b). As a control, vector-transduced progenitor 
cells were pulsed with SDF-1 (10 nM) before injection to downregulate and desensitize 
CXCR4. These cells showed the same homing defect as SDF-1VpuC-transduced HSPC 
(Fig. 6b). HSPCs expressing the MDC degrakine, which inhibited thymocyte migration to 
MDC in vitro (Fig. 5e), showed a bone marrow homing percentage similar to the control 
cells (Fig. 6b). This is consistent with the fact that CCR4 is not expressed on HSPC, and 
MDC is not expressed in the bone marrow34. These results demonstrate that CXCR4 plays 
an important role in HSPC homing to the bone marrow immediately after transplantation.
DISCUSSION
A number of chemokines and their receptors are involved in normal hemato-lymphopoiesis 
and in the immune response to pathogens. We have developed a genetic approach for the 
specific functional inactivation of CKRs in various cell types in vitro and in vivo. In stably 
transduced cell lines and mouse thymocytes or HSPCs, the degrakine does not affect cell 
proliferation or viability. The functional inactivation of CXCR4 by the SDF-1 degrakine was 
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verified by a reduction in CXCR4 expression, inhibition of SDF-1 induced calcium influx 
and blockage of chemotaxis in human T cell lines, mouse thymocytes and mouse HSPCs. 
The specificity and general utility of the degrakines were illustrated by the specific 
inactivation of their respective CKRs by SDF-1, MDC and RANTES degrakines. 
Furthermore, we used the SDF-1 degrakine to demonstrate that CXCR4 is involved in the 
homing of mouse HSPCs immediately after bone marrow transplantation, a finding that may 
partly explain the requirement of CXCR4 for the engraftment of human or mouse HSPCs in 
the mouse bone marrow compartment27–29.
The degrakine system offers a number of advantages for studying the function of CKRs in 
HSPC functions. First, it may be applicable in human HSPCs where conventional genetic 
approaches are not feasible. Second, multiple CKRs can be targeted by a single degrakine or 
by a combination of coexpressed degrakines. Finally, it is also feasible to combine the 
degrakine system with existing knockout mice to inactivate multiple CKRs.
Genetic manipulation of HSPCs from mature animals is directly relevant to clinical settings. 
The use of degrakines in these cells may elucidate the functions of specific CKRs during 
hemato-lymphopoiesis and immune responses in adults. In addition to blocking antibodies, 
which may have limited target specificity and in vivo efficacy, the intrakine system has also 
been used to inhibit CKR expression7. However, the intrakine secretes high levels of the 
intrakine protein out of the cell8 (Fig. 2b,c), is less efficient than the degrakine in 
downregulating CKR expression (Fig. 4a) and may cause an accumulation of intrakine-CKR 
proteins in the ER. In contrast, the degrakine is designed to trap the CKR in the ER and 
target it for degradation.
We envision several possible modifications of the degrakine system. First, one might be able 
to derive the CRBD from single-chain antibodies or peptides that specifically bind a target 
CKR. Such derivatives with enhanced CKR binding activity, but no agonistic or antagonistic 
activity, should substantially improve degrakine efficiency and potential applications. 
Second, the approach could be adapted to receptors other than chemokine receptors. Third, 
degrakines could be combined with stable hairpin RNAi in the retroviral system, so that the 
CKR is targeted for inactivation at both the mRNA and protein levels. This might overcome 
the variable success rate of RNAi alone. Finally, in combination with recent advances in in 
vivo imaging technology36,37, the degrakine system might be used to analyze the migration 
of HSPCs, T cells and dendritic cells in vitro and in vivo.
METHODS
Animals
All animals were housed at the University of North Carolina at Chapel Hill in a sterile 
animal facility. Total bone marrow was harvested from the tibias and femurs of 1- to 2-
month-old B6/Ly5.2 animals. Three-month-old recipient B6/Ly5.1 animals were 
administered sterile pH 2.0 water supplemented with neomycin sulfate. Lethal irradiation of 
animals (1,000 rads) was administered with a cesium source irradiator. The Institutional 
Animal Care and Use Committee approved all experiments.
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SDF-1 was cloned by PCR from the SDF-1 KDEL7 template, so that it is in-frame with 
amino acids 28–81 of Vpu (forward primer: 5′-
CGCGAATTCGCGCCATGAACGCCAAGGTCG-3′; reverse primer: 5′-CAT 
GCGGCCGCTAGCATAATCTGGAACATC-3′). Amino acids 28–81 of Vpu were cloned 
by PCR from the NL4-3 genome (forward primer: 5′-
CTAGCGGCCGCGAATATAGGAAAATATTAAGAC-3′; reverse primer: 5′-
CAGCTCGAGCACTACAGATCATCAATATCC-3′). VpuC2/6 was cloned with the same 
primers as VpuC, but using Vpu2/6 (ref. 18) as a template. All constructs were cloned into a 
high-titer retroviral vector derived from the MSCV LTR38.
Cell culture
SupT1 cells were cultured in RPMI 1640 with 10% (vol/vol) FBS and penicillin/
streptomycin. U2OS cells and 293T cells were cultured in DMEM-H with 10% (vol/vol) 
FBS and penicillin/streptomycin. Primary bone marrow was flushed from femurs and tibias, 
enriched for cKit+ cells35, cultured in IMDM containing 20% FBS (Gibco), 50 ng/ml stem 
cell factor (SCF), 50 ng/ml interleukin-6 (IL-6) and 10 ng/ml IL-11 (Peprotech) for 48 h, 
and then transduced with the indicated retroviruses. HSPC cells were maintained in IMDM 
with 10 ng/ml of SCF, IL-6 and IL-11. Thymocytes were harvested and cultured in IMDM, 
20% ES FBS, 50 ng/ml SCF and 15 ng/ml IL-7 (Peprotech).
Retrovirus production and infection
293T cells were transfected with plasmids encoding MSCV retroviral DNA, VSVg and 
gag/pol as described39. Retroviral infections by spinoculation were performed in 2 ml 
Eppendorf tubes with 1 × 106 cells with 500 µl RPMI 1640 with 10% (vol/vol) FBS, 500 µl 
of viral supernatant and 8 µg/ml polybrene. Cells were incubated at 22–24 °C for 20 min and 
centrifuged at 2000g for 3 h. Cells were either cultured as a pool or sorted for EGFP 
expression.
Immunofluorescence
The EGFP cassette in the degrakine vector was replaced with YFP-KDEL (Clontech). U2OS 
cells were transfected (Effectene, Qiagen) with the indicated DNAs. At 48 h after 
transfection, cells were fixed in 3% paraformaldehyde and permeabilized with 0.1% Triton 
X-100. Cells were stained with anti-hemagglutinin (12CA5) monoclonal and goat 
antimIgG– phycoerythrin (Pharmingen) and visualized by confocal microscopy (100×).
MTT assay
1 × 103 cells per well of EGFP-sorted SupT1 cells were plated into a 96-well plate 
(triplicate). At the indicated time points, the cells were transferred into a new 96-well plate 
containing MTT (methylthiazolydiphenyl tetrazolium bromide; Sigma) solution and 
incubated at 37 °C for 4 h. Acid-isopropanol was added and the wells were assayed with a 
microplate reader using a test wavelength of 570 nm, reference wavelength of 630 nm and 
calibration setting of 1.99 (ref. 40). All optical density (OD) readings were done in triplicate.
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Each sample (1 × 105 cells) was washed in PBS with 2% (vol/vol) FBS and stained with the 
indicated antibody in PBS with 2% (vol/vol) FBS, and 1–2 × 104 cells were collected 
through a Becton Dickinson FACScan. CXCR4 expression was detected with anti-12G5 
monoclonal antibody (NIH AIDS Reagent) and anti-mIgG–phycoerythrin (Caltag). 
Phycoerythrin–anti-CD4 and phycoerythrin–anti-MHC-I antibodies were purchased from 
Caltag. GFP-positive cells were sorted on a Cytomation MoFlo FACS. Calcium influx 
assays were performed using Indo-1 AM (Molecular Probes) as described41.
ELISA
Secreted SDF-1 was measured by ELISA (R&D Systems). 293T cells were transfected using 
Effectene (Qiagen) and cultured for 48 h. Stably transduced SupT1 cells were washed, 
plated at equal concentrations and cultured for 48 h.
Western blotting
Transduced mouse HSPCs (1 × 106 cells) or Jurkat cells (1 × 106 cells) were lysed and 
resolved by SDS-PAGE42. Gels were transferred to PVDF membranes (Amersham 
Pharmacia), blocked with 5% nonfat dry milk, probed with either anti-Vpu (1:1,000) or anti-
CXCR442 (1:100) and anti-rabbit-IgG–horseradish peroxidase (1:10,000) (Amersham 
Pharmacia). Blots were visualized using an ECL Kit (Amersham Pharmacia).
In vitro migration assay
Sorted SupT1 cells (2 × 104/well in triplicate) were assayed for migration response to SDF-1 
over 2 h using a 0.6 µm Neuroprobe ChemoTx 96-well assay plate and cell numbers were 
quantified with Packard’s ATPLite kit. 5 × 105 THP-1 cells, thymocytes or HSPCs were 
assayed for migration over a 3-h period (24-well Corning trans-well plate, 0.5 µM 
membrane) to 100 nM SDF-1 (NIH AIDS Reagent) and 100 nM Mip-1β (Peprotech). The 
percentage of migrating degrakine expressing cells was determined by FACS. (Migration % 
= migrating GFP+ cells/input GFP+ cells.)
HSPC homing assay in vivo
cKit+ B6/Ly5.2 cells were cultured for 3–6 d after retroviral transduction. In vivo homing to 
the bone marrow was determined by injection of 2 × 106 degrakines expressing cKit+ B6/
Ly5.2 cells into lethally irradiated B6/Ly5.1 mice (1,000 rads, 24 h before injection). At 3 h 
after injection the bone marrow was flushed from femurs and tibias and monitored for Ly5.2 
and GFP with a BD FACScan43. (Migration % = harvested Ly5.2+GFP+ cells/input 
Ly5.2+GFP+ cells.)
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Design and function of the degrakine system. (a) The SDF-1 degrakine consists of SDF-1 
fused to the C terminus of Vpu (aa28–81). The SDF-1 degrakine was cloned into a MSCV 
retroviral vector, which also encodes EGFP under the control of a CMV promoter. (b) The 
SDF-1 degrakine localizes to the ER, binds CXCR4 and prevents CXCR4 translocation to 
the cell surface. Additionally, VpuC interacts with β-TrCP and targets CXCR4 for 
degradation via the proteasome. HA, hemagglutinin.
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The SDF-1 degrakine localizes to the ER and is stably expressed. (a) The EGFP in the 
SDF-1 degrakine vector was replaced with YFP-KDEL. U2OS cells were transfected, 
stained with anti-HA monoclonal antibody, followed by anti-mIgG rhodamine (degrakine) 
and DAPI and visualized by confocal microscopy. (b,c) 293T cells were transfected (b) and 
SupT1 cells were transduced (c) and monitored by ELISA for SDF-1 secretion into the 
medium. Similar results were observed in two independent experiments. (d) The 
proliferation of transduced SupT1 cells was measured at the indicated time points using a 
MTT assay (OD reading). Results are representative of two independent experiments with 
each sample in triplicate. (e) Transduced SupT1 cells assayed by FACS for EGFP 
percentage at 2 d and 3 weeks in culture. (f) GFP (%) Transduced cKit+ bone marrow cells 
were monitored for EGFP percentage at 3, 6, 9 and 12 d in vitro. At day 12, 1 × 106 cells 
were harvested and assayed for degrakine expression by western blotting (anti-Vpu).
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CXCR4 expression is stably and specifically downregulated by the SDF-1 degrakine. (a) A 
representative FACS plot of independent SupT1 infections showing CXCR4 surface 
expression 1 week after transduction. (b) The cells were reanalyzed for CXCR4 expression 
at 3 and 6 weeks after transduction. (c) CD4 and MHC-I expression was monitored at the 3-
week time point. Identical results were observed in two independent experiments with 
SupT1 cells and Jurkat cells.
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The interaction between VpuC and β-TrCP is important for efficient CXCR4 
downregulation. (a) A representative FACS plot of independent SupT1 infections showing 
CXCR4 surface expression 1 week after transduction. Similar results were observed in 
Jurkat cells. (b) Total cytoplasmic lysates were analyzed by western blotting with a 
polyclonal anti-CXCR4. NIH3T3 cells stably expressing human CXCR4 were used as a 
positive control. Similar results were observed in two independent experiments.
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Degrakines specifically inhibit their target CKR function. (a) Transduced SupT1 cells were 
loaded with Indo-1AM, stimulated with SDF-1 and monitored by FACS for the change in 
Indo-1AM fluorescence. (b) Parental SupT1 cells (Mock), cells expressing vector or 
SDF-1VpuC were assayed for migration response to SDF-1 in a trans-well assay. Each 
sample was performed in triplicate and the assay is representative of two independent 
experiments. (c,d) THP-1 cells were transduced, cultured for 1 week and assayed for 
migration in response to 100 nM SDF-1 (c), or 100 nM MIP-1β (d) in a trans-well migration 
assay. (e) Mouse thymocytes were transduced, cultured for 1 week and measured for their 
migration response to 100 nM MDC in a trans-well assay. *, P < 0.05. **, P < 0.005.
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The SDF-1 degrakine inhibits CXCR4-mediated HSPC migration in vitro and homing to the 
bone marrow in vivo. (a) Transduced HSPCs (cKit+) were assayed for migration to 10 nM 
and 50 nM of SDF-1 in a trans-well assay. Each sample was performed in triplicate and the 
results are representative of two independent experiments. (b) B6/Ly5.2+ HSPCs (cKit+) 
were transduced, injected into lethally irradiated B6/Ly5.1 recipients and harvested from the 
recipient’s bone marrow 3 h after transplantation. Vector + SDF-1 cells were vector-
transduced cells pulsed with 10 nM of SDF-1 immediately before injection. Three mice 
were used for each vector and the assay is representative of two independent experiments. *, 
P < 0.005. **, P < 0.005.
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